Related by context. All words. (Click for frequent words.) 79 chemoradiation 78 neoadjuvant chemotherapy 76 chemoradiation therapy 76 neoadjuvant treatment 76 neoadjuvant therapy 74 adjuvant radiotherapy 74 carboplatin paclitaxel 73 TACE 73 postoperative chemotherapy 73 adjuvant therapy 73 preoperative chemotherapy 73 pegylated liposomal doxorubicin 73 concurrent chemoradiation 73 lymphadenectomy 73 neoadjuvant 73 Doxil ® 72 adjuvant radiation 72 debulking surgery 72 resectable 72 cytoreduction 72 5FU 71 mycophenolate mofetil 71 androgen deprivation 71 pancreatic adenocarcinoma 71 cystectomy 71 metastatic RCC 71 5-FU/LV 71 liver resection 71 external beam radiotherapy 71 paclitaxel carboplatin 71 chemoembolization 71 locoregional 71 chemo radiotherapy 70 gemcitabine chemotherapy 70 metastatic renal cell carcinoma 70 EBRT 70 clinically localized prostate 70 nab paclitaxel 70 recurrent metastatic 70 cisplatin chemotherapy 70 Torisel 70 pelvic lymphadenectomy 70 goserelin 70 ABVD 70 cytoreductive surgery 70 docetaxel chemotherapy 70 sorafenib Nexavar 70 chemotherapeutic regimens 70 epirubicin 70 axillary dissection 70 hepatic metastases 70 cytotoxic chemotherapy 70 zalutumumab 70 IV NSCLC 70 FOLFOX6 70 postoperative radiotherapy 70 transurethral resection 70 metastatic malignant 70 CHOP chemotherapy 70 FOLPI 69 temsirolimus 69 fluorouracil 69 pegylated interferon alfa 2b 69 antithrombotic therapy 69 radiochemotherapy 69 stage IIIB 69 mRCC 69 locoregional recurrence 69 irinotecan chemotherapy 69 androgen ablation 69 cabazitaxel 69 gemcitabine carboplatin 69 heavily pretreated patients 69 DAPT 69 Adjuvant chemotherapy 69 GnRH agonist 69 BEACOPP 69 docetaxel 69 radical cystectomy 69 bleomycin 69 tumor resection 69 SCCHN 69 recurrent glioblastoma multiforme 69 adjuvant tamoxifen 69 Proxinium TM 69 chlorambucil 69 platinum refractory 69 intravenous bisphosphonates 69 recurrent prostate cancer 69 topotecan 69 antiangiogenic therapy 69 colorectal liver metastases 69 lymph node dissection 69 lenalidomide dexamethasone 69 eptifibatide 69 TORISEL 69 ZACTIMA 68 radiotherapy RT 68 sentinel lymph node biopsy 68 chemotherapy docetaxel 68 Neoadjuvant 68 fallopian tube carcinoma 68 radical nephrectomy 68 androgen suppression 68 Gemcitabine 68 NMIBC 68 metastatic malignant melanoma 68 parathyroidectomy 68 taxane chemotherapy 68 zoledronic acid 68 cinacalcet 68 gefitinib Iressa 68 adalimumab 68 Surgical resection 68 sunitinib 68 gemcitabine Gemzar 68 estramustine 68 adjuvant chemotherapy 68 curative resection 68 FOLFIRI 68 unresectable 68 FOLFOX4 68 biochemical relapse 68 mitoxantrone 68 ALA PDT 68 Pemetrexed 68 Amrubicin 68 prostate carcinoma 68 standard chemotherapy regimen 68 liposomal doxorubicin 68 pain palliation 68 pertuzumab 68 nephrectomy 68 pneumonectomy 68 surgical debulking 68 dacarbazine 68 Fludara 68 distant metastases 68 relapsed ovarian cancer 68 cetuximab 68 urothelial carcinoma 68 gemcitabine 68 ximelagatran 68 doxorubicin docetaxel 68 refractory ovarian cancer 67 APTIVUS r 67 Xelox 67 ribavirin RBV 67 ibandronate 67 rFVIIa 67 tamoxifen therapy 67 malignant pleural mesothelioma 67 5-fluorouracil/leucovorin 67 methotrexate monotherapy 67 taxane therapy 67 breast carcinoma 67 bevacizumab Avastin 67 biochemical recurrence 67 biliary tract cancer 67 patients undergoing CABG 67 oral clodronate 67 nonmetastatic 67 interferon ribavirin 67 non squamous NSCLC 67 idraparinux 67 chemotherapy cisplatin 67 idarubicin 67 clodronate 67 operable breast cancer 67 docetaxel Taxotere ® 67 imatinib therapy 67 bevacizumab 67 cisplatin 67 XELOX 67 tumor recurrence 67 Taxotere ® 67 CLL SLL 67 medically inoperable 67 docetaxel Taxotere 67 pCR 67 ALND 67 multimodality therapy 67 decitabine 67 cytoreductive nephrectomy 67 teriflunomide 67 chemotherapeutic regimen 67 azacitidine 67 neurologic progression 67 Irinotecan 67 prostate cancer CaP 67 Hepatocellular Carcinoma HCC 67 LHRH agonists 67 recurrent GBM 67 PSADT 67 LHRH receptor positive 67 colorectal cancer liver metastases 67 liver metastases 67 GnRH agonists 67 intraperitoneal chemotherapy 67 epirubicin cyclophosphamide 67 dose dexamethasone 67 ixabepilone 67 tocilizumab 67 distant metastasis 67 Thal Dex 67 metastatic lung cancer 67 CA4P 67 beta blocker therapy 67 galiximab 67 liver metastasis 67 adriamycin 67 adjuvant therapies 67 fluoropyrimidine 67 Oxaliplatin 67 Cetuximab 66 thromboprophylaxis 66 pyridostigmine 66 underwent resection 66 thromboembolic events 66 superficial bladder cancer 66 oral anticoagulation 66 lenalidomide Revlimid R 66 FOLFIRINOX 66 Natalizumab 66 etoposide 66 anastrozole 66 FOLFOX 66 recurrent NSCLC 66 TTF Therapy 66 paclitaxel poliglumex 66 β blockers 66 histologically confirmed 66 fondaparinux 66 placebo dexamethasone 66 tamsulosin 66 trabectedin 66 Pegylated Interferon 66 FDG-PET/CT 66 infusional 5-FU/LV 66 F FDG PET 66 peritoneal carcinomatosis 66 CYPHER Stent 66 palliation 66 recurrent malignant glioma 66 bendamustine 66 HIPEC 66 remission CR 66 TroVax ® 66 capecitabine Xeloda 66 MGd 66 daunorubicin 66 ELACYT 66 Cytoxan 66 NATRECOR ® 66 sustained virological response 66 CTEPH 66 EUS FNA 66 thoracoscopic lobectomy 66 conventional angiography 66 mitomycin 66 Kaplan Meier analysis 66 relapsed MM 66 trastuzumab 66 fulvestrant 66 malignant ascites 66 intra arterial chemotherapy 66 axillary lymph node dissection 66 nonrandomized 66 corticosteroid therapy 66 vandetanib 66 intestinal metaplasia 66 Capecitabine 66 DOXIL 66 endoscopic resection 66 elacytarabine 66 HuMax EGFr 66 ritonavir boosted 66 stent implantation 66 cytotoxic therapy 66 lung resection 66 ACTEMRA TM 66 antitumor effect 66 esophageal carcinoma 66 alteplase 66 cranial radiation 66 renal tumors 66 adjuvant cisplatin 66 SLNB 66 peg interferon 66 intravesical 66 trastuzumab Herceptin ® 66 sunitinib malate 66 metastatic bladder 66 HSCT 66 Trastuzumab 66 vinorelbine 66 RECIST criteria 66 nodal metastases 66 nephron sparing surgery 66 methotrexate therapy 66 thalidomide Thalomid 66 mitomycin C 66 FASLODEX 66 revascularization procedures 66 sentinel node biopsy 66 advanced hepatocellular carcinoma 66 node dissection 66 paricalcitol 65 aromatase inhibitor therapy 65 HNSCC 65 esophagectomy 65 low dose dexamethasone 65 CIMZIA TM 65 metastatic gastric 65 mycophenolate mofetil MMF 65 adenoma recurrence 65 anti angiogenic therapy 65 DMARD therapy 65 paclitaxel Taxol R 65 mitoxantrone chemotherapy 65 KRAS mutations occur 65 HER2 positive metastatic breast 65 virologic response 65 autologous transplants 65 immunosuppressive regimen 65 prostate cancer PCa 65 endometrial carcinoma 65 metastatic colorectal 65 Surgical excision 65 Lenalidomide 65 warfarin therapy 65 VATS lobectomy 65 pemetrexed 65 CIMZIA ™ 65 carboplatin 65 mCRC patients 65 subgroup analyzes 65 Mitomycin C 65 injected subcutaneously 65 adrenalectomy 65 thrombolytic therapy 65 #Gy 65 catheter angiography 65 postoperative morbidity 65 unfractionated heparin UFH 65 Peg IFN 65 PSA nadir 65 MabCampath 65 nonoperative 65 CsA 65 STRIDE PD 65 symptomatic VTE 65 ASCT 65 Degarelix 65 doxorubicin cyclophosphamide 65 antiplatelet therapy 65 cilostazol 65 liposomal amphotericin B 65 ER CHOP 65 Platinol ® cisplatin 65 localized renal 65 palliative radiotherapy 65 depsipeptide 65 cyclophosphamide 65 Cystectomy 65 plus dexamethasone 65 stage IIIb IV 65 Bezielle 65 dose cytarabine 65 iniparib BSI 65 decompressive surgery 65 NSTE ACS 65 axitinib 65 thymoma 65 postoperative complication 65 fallopian tube cancers 65 pT2 65 RTOG 65 complete cytogenetic response 65 complete remissions 65 EFAPROXYN 65 plus gemcitabine 65 elective PCI 65 oral Xeloda 65 advanced unresectable 65 myocardial revascularization 65 Vicinium TM 65 DMARD 65 cediranib 65 rt PA 65 salmeterol fluticasone 65 PAOD 65 transarterial 65 mapatumumab 65 biologic DMARD 65 pamidronate 65 gemcitabine cisplatin 65 anthracycline taxane 65 colectomy 65 octreotide LAR 65 gemcitabine Gemzar ® 65 CMV disease 65 CR nPR 65 AGILECT R 65 eribulin mesylate 65 EndoTAGTM 1 65 assessing T DM1 65 metastatic GIST 65 bevacizumab Avastin ® 65 oral rivaroxaban 65 TURBT 65 oncologic outcomes 65 stereotactic radiotherapy 65 iniparib 65 infusional 65 #F FDG PET 65 hormonal therapy 65 urothelial bladder cancer 65 Subgroup analysis 65 eplerenone 65 trials RCTs 65 Radical prostatectomy 65 pomalidomide 65 GP IIb IIIa inhibitors 65 exemestane 65 locoregional disease 65 Flu Cy 65 EGFR TKI 65 invasive candidiasis 65 fluorouracil leucovorin 65 TEMODAL 65 PegIFN RBV 65 peritoneal cancer 65 pazopanib 65 temozolomide TMZ 65 Taxotere R 64 adecatumumab 64 Toxicities 64 KRAS status 64 xenograft models 64 unresectable tumors 64 bisphosphonate therapy 64 Platinol ® 64 FDG PET 64 EGFR expressing 64 Ceplene/IL-2 64 postoperative mortality 64 cisplatin gemcitabine 64 H. pylori eradication 64 rituximab Rituxan 64 hypofractionated 64 TAXOTERE R 64 CIN3 64 Velcade bortezomib 64 intravenous cyclophosphamide 64 adalimumab Humira 64 Folfox 64 TURP 64 tenecteplase 64 papillary renal cell carcinoma 64 Combination therapy 64 trastuzumab Herceptin 64 oral anticoagulant therapy 64 patients evaluable 64 radioiodine therapy 64 perioperatively 64 octreotide 64 intravesical therapy 64 virological response 64 differentiated thyroid 64 metastatic CRC 64 melphalan prednisone 64 standard chemotherapy regimens 64 DFMO 64 cilengitide 64 biologic therapy 64 pT3 64 comparator arm 64 oral diclofenac 64 VFEND 64 preoperative radiotherapy 64 micafungin 64 mg kg dose 64 anti angiogenic agents 64 dose melphalan 64 neoadjuvant chemoradiotherapy 64 severe oral mucositis 64 mucinous 64 ELOXATIN 64 gefitinib 64 total thyroidectomy 64 caspofungin 64 ovarian carcinoma 64 CANCIDAS 64 BCG refractory 64 partial remissions 64 myeloablative 64 recurrent squamous cell carcinoma 64 orchiectomy 64 ARB telmisartan 64 GISTs 64 alkylating agent 64 RECIST Response Evaluation Criteria 64 tirofiban 64 metastatic disease 64 YERVOY 64 adjuvant hormonal therapy 64 Pegasys plus Copegus 64 antithymocyte globulin 64 platelet inhibitor 64 stage IIIA 64 Elitek 64 rituximab 64 mg/m2 dose 64 relapsed CLL 64 sustained virologic response 64 chemotherapy regimens 64 radical prostatectomy RP 64 phase IIb study 64 invasive coronary angiography 64 Mitoxantrone 64 nodal metastasis 64 glatiramer acetate 64 refractory AML 64 irbesartan 64 Paraplatin ® 64 Decitabine 64 paclitaxel chemotherapy 64 duplex ultrasonography 64 R0 resection 64 QTc prolongation 64 imatinib 64 Sorafenib 64 levosimendan 64 underwent surgical resection 64 temozolomide 64 radiofrequency ablation RFA 64 lobectomy 64 Fluorouracil 64 micrometastasis 64 histologically proven 64 antimicrobial prophylaxis 64 percutaneous cryoablation 64 letrozole 64 Chemoradiation 64 antibiotic prophylaxis 64 leukemia AML 64 YONDELIS 64 VIDAZA 64 intraperitoneal therapy 64 MAGE A3 ASCI 64 intra arterial 64 microwave hyperthermia 64 paclitaxel Taxol 64 brain metastases 64 luteinizing hormone releasing 64 enzastaurin 64 contralateral breast 64 oral Hycamtin 64 Erlotinib 64 thalidomide dexamethasone 64 metastatic prostate cancer 64 prostate cancer CRPC 64 resected 64 riociguat 64 tipranavir ritonavir 64 azacytidine 64 receiving VICTRELIS 64 teriparatide 64 infliximab Remicade 64 argatroban 64 paragangliomas 64 mediastinoscopy 64 Free Survival PFS 64 median PFS 64 Gliadel Wafer 64 randomized multicenter trial 64 haematologic 64 CTAP# Capsules 64 peginterferon 64 dose cohort 64 abacavir Ziagen 64 nonmelanoma skin cancers 64 antiarrhythmic drugs 64 alpha blocker 64 receptor tyrosine kinase inhibitor 64 tumor histology 64 cervical carcinoma 64 IFN alfa 64 bortezomib 64 Hycamtin ® 64 tumor regressions 64 interferon alfa 64 dacarbazine chemotherapy 64 Hazard Ratio 64 doublet chemotherapy 64 cisplatin vinorelbine 64 remission induction 64 metastatic HRPC 64 docetaxel prednisone 64 gastrointestinal stromal tumor GIST 64 OPCAB 64 PEG interferon 63 cyclophosphamide methotrexate 63 transarterial chemoembolization 63 pegfilgrastim 63 HER2 overexpression 63 surrogate endpoint 63 oxaliplatin 63 gastroesophageal junction 63 beam radiotherapy 63 hematologic toxicity 63 Adjuvant therapy 63 pimecrolimus 63 BoNTA 63 reinfarction 63 hydroxychloroquine 63 drug eluting stent implantation 63 strontium ranelate 63 PROCHYMAL 63 oblimersen 63 olaparib 63 IRX 2 63 evaluable patients 63 bronchial thermoplasty 63 gadolinium enhanced 63 5 fluorouracil 63 nadolol 63 tamoxifen Nolvadex ® 63 nonsmall cell lung cancer 63 unfractionated heparin 63 dasatinib 63 viral kinetics 63 recurrent glioblastoma 63 SBRT 63 ARIMIDEX 63 capecitabine 63 TRUS biopsy 63 Traficet EN 63 Platinol 63 Acute Coronary Syndromes ACS 63 letrozole Femara 63 achieved ACR# 63 TKI therapy 63 flutamide 63 vaginal hysterectomy 63 bolus dose 63 radiation therapy 63 recanalization 63 TYKERB 63 CBLC# 63 inhibitor RG# 63 resectable pancreatic cancer 63 weekly subcutaneous injections 63 brivaracetam 63 endosonography 63 perioperative mortality 63 spiral computed tomography 63 intra articular injection 63 DVT prophylaxis 63 sorafenib 63 imatinib Gleevec 63 basal cell carcinoma BCC 63 Allovectin 7 ® 63 CIMZIA TM certolizumab pegol 63 iodixanol 63 mTOR inhibitors 63 liver biopsies 63 glycoprotein IIb IIIa inhibitor 63 bone metastasis 63 androgen deprivation therapy 63 OPAXIO 63 undetectable HBV DNA 63 Retreatment 63 HoLEP 63 nonoperative treatment 63 monotherapy 63 salpingo oophorectomy 63 bone metastases 63 CCyR 63 chemotherapy gemcitabine 63 CR CRu 63 immunomodulatory therapy 63 vorinostat 63 epithelial ovarian cancer 63 indolent lymphomas 63 unresectable stage 63 fibrinolytic therapy 63 posaconazole 63 complete cytogenetic 63 etanercept Enbrel 63 farletuzumab 63 relapsed AML 63 HRPC 63 somatostatin analog 63 paroxysmal AF 63 subtrochanteric 63 gastric adenocarcinoma 63 NovoTTF 63 OncoVEX GM CSF 63 sipuleucel T 63 HBeAg seroconversion 63 randomized trials 63 interferon alfa 2b 63 intratumoral 63 cerebral vasospasm 63 sirolimus eluting stents 63 lipid lowering therapy 63 interferon beta therapy 63 azathioprine 63 cytogenetic responses 63 VTE prophylaxis 63 cardiac toxicity 63 relapsing MS 63 androgen blockade 63 neo adjuvant 63 peginterferon alfa 2a 63 variceal hemorrhage 63 stratifying patients 63 coronary angiography 63 carotid artery stenting 63 Vandetanib 63 tolvaptan 63 chronic periodontitis 63 anticoagulation therapy 63 lymph node metastases 63 KRAS wild 63 postoperative atrial fibrillation 63 conventional DMARDs 63 huN# DM1 63 active comparator 63 gadobutrol 63 cytogenetic response 63 endarterectomy 63 lung metastases 63 pediatric malignancies 63 cytogenetic abnormalities 63 alpha 2a 63 inotropic 63 partial nephrectomy 63 node metastases 63 mCi kg 63 grade cervical intraepithelial 63 genotypic resistance 63 Telintra 63 intradermal injection 63 BENICAR HCT 63 follicular NHL 63 recurrent venous thromboembolism 63 CYT# potent vascular disrupting 63 SUTENT 63 histological subtype 63 baminercept 63 hepatectomy 63 bone scintigraphy 63 Helicobacter pylori eradication 63 epithelial tumors 63 NSABP B 63 Protelos 63 8mg/kg 63 relapsed SCLC 63 Mylotarg 63 variceal bleeding 63 subconjunctival injection 63 metastatic bone 63 PEG IFN 63 overlapping toxicities 63 invasive bladder 63 multicentre randomized 63 abacavir lamivudine 63 Pegylated Liposomal Doxorubicin 63 Carboplatin 63 gastrointestinal stromal tumors GIST 63 sorafenib Nexavar ® 63 pancreatic carcinoma 63 endometrial hyperplasia 63 coronary revascularization 63 rFSH 63 Fludarabine 63 interferon alfa 2a 63 lapatinib Tykerb 63 PREZISTA r 63 pegylated interferon alfa 63 metastatic pancreatic 63 triphendiol 63 PASI scores 63 bovine thrombin 63 SLN biopsy 63 Aplidin 63 relapsing multiple sclerosis 63 glucocorticoid therapy 63 urothelial cancer 63 durable remissions 63 low dose cytarabine 63 timepoints 63 tumor shrinkage 63 Dacogen decitabine 63 allogeneic stem cell 63 ciclosporin 63 nephrotoxicity 63 nonmetastatic prostate cancer 63 doxorubicin HCl 62 glycoprotein IIb IIIa inhibitors 62 Vectibix monotherapy 62 saline placebo 62 deferoxamine 62 resections 62 budesonide foam 62 colorectal adenoma 62 ISF# 62 bicalutamide 62 erlotinib 62 randomized Phase IIb 62 extracranial 62 symptomatic paroxysmal AF 62 perioperative morbidity 62 APTIVUS 62 Peginterferon 62 pulmonary artery banding 62 NATRECOR R 62 fluticasone salmeterol 62 Fontan procedure 62 clopidogrel Plavix 62 Sanofi Aventis Taxotere 62 Metastatic Prostate Cancer 62 intralesional 62 AA Amyloidosis 62 FUSILEV enhances 62 PCa 62 eosinophilic asthma 62 coronary intervention 62 calcineurin inhibitor 62 HER2 negative 62 carcinoids 62 RF ablation 62 conformal radiotherapy 62 hepatic resection 62 refractory prostate cancer 62 BCIRG 62 folinic acid 62 Hydroxyurea 62 tipranavir 62 apremilast 62 indolent NHL 62 erlotinib Tarceva ® 62 rosuvastatin #mg 62 basiliximab 62 LHRH agonist 62 thyroid nodules 62 antihypertensive therapy 62 leiomyomas 62 antiangiogenic agent 62 prospective multicenter 62 resected pancreatic cancer 62 prospectively defined 62 Bevacizumab 62 ATACAND 62 CRp 62 anastrazole 62 PSMA ADC 62 #mg BID [001] 62 symptomatic intracranial 62 intraperitoneal 62 stage IIIb 62 virologic failure 62 immunohistochemical staining 62 cidofovir 62 fluvastatin 62 revascularisation 62 tiotropium 62 Tavocept 62 randomized blinded 62 tumor necrosis 62 erlotinib Tarceva 62 anticoagulant therapy 62 chemoresistant 62 angiographic outcomes 62 esophagogastric 62 pyrazinamide 62 FIRMAGON 62 INTELENCE 62 Hycamtin 62 prednisone prednisolone 62 dasatinib Sprycel 62 bladder carcinoma 62 myocardial necrosis 62 hepatocellular carcinoma HCC 62 Anti Bacterial Envelope 62 prostate cancer mCRPC 62 invasive carcinoma 62 glargine 62 Neulasta ® 62 cervical lymph nodes 62 5 fluorouracil leucovorin 62 Xanafide 62 carcinoid tumors 62 chemotherapeutic drug 62 Temsirolimus 62 LPV r 62 dose escalation 62 FOLFIRI alone 62 squamous cell carcinoma SCC 62 antifungal therapy 62 severe neutropenia 62 neratinib 62 surgical revascularization 62 aortic root replacement 62 FDG PET imaging 62 hepatocellular carcinomas 62 exemestane Aromasin 62 TNF inhibitor 62 hormonal therapies 62 EXJADE 62 CPOP R 62 morphometric vertebral fractures 62 ErbB2 positive 62 #mg/m# [002] 62 primary patency 62 placebo controlled clinical 62 composite endpoint 62 6 mercaptopurine 62 Inhaled nitric oxide 62 Faslodex 62 lymph node metastasis 62 GW# [003] 62 icatibant 62 resistant ovarian cancer 62 AVODART 62 gemtuzumab ozogamicin 62 allogeneic hematopoietic stem cell 62 metastatic hormone refractory 62 NSABP 62 cerebrovascular events 62 percutaneous drainage 62 prospective randomized controlled 62 bezafibrate 62 thromboembolic 62 IFN beta 62 gastrectomy 62 NCCTG N# 62 completely resected 62 prospectively randomized 62 relapsed refractory 62 sunitinib Sutent 62 advanced adenomas 62 systemic ALCL 62 visilizumab 62 everolimus eluting stents 62 Navelbine ® 62 percutaneous nephrolithotomy 62 ipsilateral stroke 62 ICD therapy 62 sleeve lobectomy 62 transplantation HCT 62 thromboembolic disease 62 Camptosar ® 62 RoACTEMRA 62 severe exacerbations 62 ToGA 62 coronary stenting 62 anti leukemic 62 percutaneous vertebroplasty 62 macroalbuminuria 62 neuroendocrine carcinoma 62 opioid analgesia 62 bortezomib Velcade 62 allogeneic HSCT 62 prostate TURP 62 oxaliplatin Eloxatin 62 transabdominal 62 IV bisphosphonates 62 Vidaza azacitidine 62 recurrent VTE 62 periprocedural 62 zoledronate 62 chemotherapy regimen 62 hepatorenal syndrome 62 BRIM2 62 IFN α 62 NLX P# 62 tumor regression 62 binary restenosis 62 Halaven 62 PROMACTA 62 Capesaris 62 dexamethasone Decadron 62 rindopepimut 62 aspirin clopidogrel 62 antiplatelet medication 62 Herceptin trastuzumab 62 Response Evaluation Criteria 62 heavily pretreated 62 Nexavar sorafenib 62 conventional coronary angiography 62 lymph node involvement 62 oral allopurinol 62 docetaxel Taxotere R 62 Myelodysplastic Syndrome MDS 62 lymphocytosis